Alzheimer disease, dementia

Acetylcholinesterase Inhibitor

Bioavailability: 100%
Protein binding: approximately 96%
Hepatic metabolism: P450 CYP2D6 and CYP3A4, extensive metabolism, glucuronidation
Excretion: Fecal 15%, Renal 57%, 17% unchanged
Elimination: Half Life: about 70 hr

Hypersensitivity to donepezil or piperidine derivatives. Use with caution in patients with active gastrointestinal diseases, asthma, COPD, seizure, and sick sinus syndrome.

C

Infant risk cannot be ruled out.

nausea, vomiting, diarrhea, muscle cramps, insomnia, fatigue, and anorexia

Adults:
mild-to-moderate Alzheimer's disease: initial, 5 mg orally once daily at bedtime; if suboptimal clinical response, may increase to MAX of 10 mg orally once daily at 4 to 6 weeks